Snapshot from Jun 09, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / SERB_Pharmaceuticals acquires Idefirix rights
Business acquisition

SERB_Pharmaceuticals acquires Idefirix rights

Analysis based on 7 articles · First reported May 19, 2026 · Last updated May 19, 2026

Sentiment
60
Attention
4
Articles
7
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The acquisition of Imlifidase rights by SERB Pharmaceuticals>>> from GT Biopharma>>> is expected to positively impact both companies. GT Biopharma>>> will receive a significant cash injection, potentially boosting its stock price, while SERB Pharmaceuticals>>> expands its portfolio in a specialized market, which could lead to increased revenue and market share.

Pharmaceuticals Biotechnology
Event Summary

SERB Pharmaceuticals>>> has entered into an agreement to acquire the exclusive development and commercialization rights to Imlifidase (imlifidase) in the European Union>>>, United Kingdom>>>, Switzerland>>>, Norway>>>, Liechtenstein>>>, Iceland>>>, and the Europe, the Middle East and Africa>>> region from GT Biopharma>>> for 115 million euros. Imlifidase is a treatment for highly sensitized adult patients awaiting kidney transplants from deceased donors, addressing a significant unmet medical need. Under the terms, GT Biopharma>>> will receive an upfront payment of 110 million euros and an additional 5 million euros upon acceptance of the filing for full approval of Imlifidase by the European Union — European Medicines Agency>>>. GT Biopharma>>> will support SERB Pharmaceuticals>>> in the EMA filing and review process, while SERB Pharmaceuticals>>> will take over responsibility for post-authorization studies. The transaction is subject to regulatory approval and is expected to close within 60 days. This deal allows SERB Pharmaceuticals>>> to expand its presence in rare and urgent conditions and provides GT Biopharma>>> with substantial capital.

Key Actions
100 SERB Pharmaceuticals acquired rights GT Biopharma
90 GT Biopharma received payment SERB Pharmaceuticals
70 GT Biopharma will support SERB Pharmaceuticals
70 SERB Pharmaceuticals will assume responsibility
50 United States — Food and Drug Administration accepted application
Entities Involved
priv
SERB Pharmaceuticals
SERB Pharmaceuticals>>> acquired exclusive development and commercialization rights to Imlifidase in Europe and MENA, expanding its portfolio in rare and urgent conditions.
Importance 90 Sentiment 70
stock
GT Biopharma
GT Biopharma>>> divested the European and MENA rights to Imlifidase for 115 million euros, allowing it to focus on other markets and receive significant payments.
Importance 90 Sentiment 60
oth
Imlifidase
Imlifidase>>> is the key drug being acquired, a treatment for highly sensitized adult patients prior to kidney transplant, which will now be commercialized by SERB Pharmaceuticals>>> in specific regions.
Importance 80 Sentiment 70
govactor
European Union — European Medicines Agency
The European Union — European Medicines Agency>>> is involved in the approval process for Imlifidase>>>, with a payment contingent on its filing acceptance.
Importance 50 Sentiment 0
alliance
European Union
The European Union>>> is a key region where SERB Pharmaceuticals>>> will acquire rights to Imlifidase>>>.
Importance 40 Sentiment 0
loc
Europe, the Middle East and Africa
The Europe, the Middle East and Africa>>> region is a key area where SERB Pharmaceuticals>>> will acquire rights to Imlifidase>>>.
Importance 40 Sentiment 0
cnt
United Kingdom
The United Kingdom>>> is one of the regions where SERB Pharmaceuticals>>> will acquire rights to Imlifidase>>>.
Importance 30 Sentiment 0
cnt
Switzerland
Switzerland>>> is one of the regions where SERB Pharmaceuticals>>> will acquire rights to Imlifidase>>>.
Importance 30 Sentiment 0
cnt
Norway
Norway>>> is one of the regions where SERB Pharmaceuticals>>> will acquire rights to Imlifidase>>>.
Importance 30 Sentiment 0
cnt
Liechtenstein
Liechtenstein>>> is one of the regions where SERB Pharmaceuticals>>> will acquire rights to Imlifidase>>>.
Importance 30 Sentiment 0
cnt
Iceland
Iceland>>> is one of the regions where SERB Pharmaceuticals>>> will acquire rights to Imlifidase>>>.
Importance 30 Sentiment 0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration>>> accepted the Biologics License Application for imlifidase in the US, indicating future market potential outside the current deal.
Importance 20 Sentiment 0
priv
Rothschild & Co
Rothschild & Co>>> acted as the exclusive financial advisor to SERB Pharmaceuticals>>> for this transaction.
Importance 10 Sentiment 0
priv
Freshfields
Freshfields>>> acted as legal counsel to SERB Pharmaceuticals>>>.
Importance 10 Sentiment 0
priv
Centerview Partners
Centerview Partners>>> acted as the exclusive financial advisor to GT Biopharma>>>.
Importance 10 Sentiment 0
+ 1 more entities View on Dashboard
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.